BASF to Introduce Two Isobionics Natural Flavor Ingredients

BASF SE’s BASFY Aroma Ingredients brand, Isobionics, is set to launch two new natural ingredients, Isobionics Natural beta-Sinensal 20 and Isobionics Natural alpha-Humulene 90, for the flavor market. These are produced using a cutting-edge fermentation process. Isobionics Natural alpha-Humulene 90 is geared for applications in beverages and essential oils.

BASF has been investing in innovations and the launch of these products is a part of this effort. The Isobionics Natural beta-Sinensal 20 has a potential for wide use in savory formulations, adding juiciness to any flavour or enhancing the organoleptic properties of orange oil products. The Isobionics Natural alpha-Humulene 90 is a woody flavor ingredient with high purity and is suitable for non-alcoholic as well as alcoholic beverages. This is a perfect choice for hop oil applications. 

The manufacturing process of both ingredients entails fermentation from readily available renewable raw materials and is independent from weather and harvest conditions, enabling consistent premium quality as well as reliable availability. BASF’s dedicated team for Specialty Aroma Ingredients has been continuously driving such product innovations to keep up with current and future trends.

BASFY stock has lost 7.9% in the past year compared with the 16.6% decline in the industry.

Zacks Investment Research
Image Source: Zacks Investment Research

BASFY’s Zacks Rank and Key Picks

BASFY currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Ingevity Corporation NGVT, Axalta Coating Systems AXTA and Carpenter Technology Corporation CRS. While NGVT and AXTA sport a Zacks Rank #1 (Strong Buy) each at present, CRS carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Ingevity’s current-year earnings is pegged at $4.45 per share. NGVT’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with the average surprise being 202.9%.

The Zacks Consensus Estimate for Axalta’s current-year earnings is pegged at $2.51 per share. AXTA’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 16.28%.

The Zacks Consensus Estimate for Carpenter Technology’s current fiscal-year earnings is pegged at $6.95 per share. CRS’ earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 15.7%. Its shares have soared 169.5% in the past year.



 

Only $1 to See All Zacks' Buys and Sells

We're not kidding.

Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.

Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BASF SE (BASFY) : Free Stock Analysis Report

Carpenter Technology Corporation (CRS) : Free Stock Analysis Report

Axalta Coating Systems Ltd. (AXTA) : Free Stock Analysis Report

Ingevity Corporation (NGVT) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.
More articles by this source
Stocks Mentioned

Latest Articles

Data is currently not available